Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C17H15ClN2O |
| Molecular Weight | 298.767 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1(N2CCCN=C2C3=C1C=CC=C3)C4=CC=C(Cl)C=C4
InChI
InChIKey=ZGLAJTSGABGHND-UHFFFAOYSA-N
InChI=1S/C17H15ClN2O/c18-13-8-6-12(7-9-13)17(21)15-5-2-1-4-14(15)16-19-10-3-11-20(16)17/h1-2,4-9,21H,3,10-11H2
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-Homomazindol
Created by
admin on Sat Dec 16 10:24:27 GMT 2023 , Edited by admin on Sat Dec 16 10:24:27 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
HOMOMAZINDOL
Created by
admin on Sat Dec 16 10:24:27 GMT 2023 , Edited by admin on Sat Dec 16 10:24:27 GMT 2023
|
PRIMARY | While mazindol is used in doses up to 4 mg, homomazindol displays neglible effects at that range. Increasing the dose to 10-25 mg was required to produce an effect. | ||
|
36951-86-7
Created by
admin on Sat Dec 16 10:24:27 GMT 2023 , Edited by admin on Sat Dec 16 10:24:27 GMT 2023
|
PRIMARY | |||
|
12204576
Created by
admin on Sat Dec 16 10:24:27 GMT 2023 , Edited by admin on Sat Dec 16 10:24:27 GMT 2023
|
PRIMARY | |||
|
ZM6V5Z8UXP
Created by
admin on Sat Dec 16 10:24:27 GMT 2023 , Edited by admin on Sat Dec 16 10:24:27 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
